| Autor: |
Duijvelaar E; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Schippers JR; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Smeele PJ; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., de Raaf MA; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Vanhove ALEM; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Blok SG; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Twisk JWR; Department of Epidemiology and Data Science, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Vonk Noordegraaf A; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., de Man FS; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Bogaard HJ; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands., Aman J; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands. Electronic address: j.aman@amsterdamumc.nl. |
| Abstrakt: |
Competing Interests: JA and AVN are inventors on a patent (WO2012150857A1, 2011) covering protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase Abl-related gene (Arg). All other authors have no competing interests. ED and JRS contributed equally. Members of the CounterCOVID study group are listed in the appendix (p 12). This project was funded with an unrestricted grant from the Amsterdam Medical Center Foundation, a bottom-up grant from NWO ZonMW (number 10430 01 201 0007), and from the Innovative Medicines Initiative 2 Joint Undertaking (number 101005142). The funding sources had no role in the design of the study, data collection, analysis, or in the decision to submit the paper for publication. |
